Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Hemisuccinate Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 11/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.85 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | PGR | P06401 | 4/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.80 |
| ▸ | AR | P10275 | 2/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | FNTA | P49354 | 1/20 | 0.72 |
| ▸ | FNTB | P49356 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2807 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2025264805-A2 | SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4618933-A1 | SYSTEMS, METHODS, AND APPARATUSES FOR DRUG INJECTORS | SOLUtion Medical, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| CN-120201983-A | Systems, methods, and apparatus for a drug injection device | 解决方案医疗公司 | 2025-06-24 | — | — | CN | claimed |
| EP-0752898-B1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORP (US) | 1998-04-29 | — | — | EP | claimed |
| WO-1998012304-A1 | CULTURE SYSTEM FOR HEMATOPOIETIC STEM CELLS | MEDICAL RESEARCH COUNCIL (GB) | 1998-03-26 | — | — | WO | claimed |
| EP-0752898-A1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORPORATION (US) | 1997-01-15 | — | — | EP | claimed |
| WO-1995026782-A1 | REDUCTION OF SKIN IRRITATION DURING ELECTROTRANSPORT DELIVERY | ALZA CORPORATION (US) | 1995-10-12 | — | — | WO | claimed |
| US-5173302-A | 2-acrylamido-2-methyl propanesulfonic acid copolymer, ethylene /propylene oxide derivative humectant, crosslinking monomer, initiator | MEDTRONIC, INC. (US) | 1992-12-22 | — | — | US | claimed |
| EP-0503009-A1 | HYDROPHILIC PRESSURE SENSITIVE ADHESIVE FOR TOPICAL ADMINISTRATION OF HYDROPHOBIC DRUGS | LUDLOW CORPORATION (US) | 1992-09-16 | — | — | EP | claimed |
| US-5112757-A | METHOD FOR OBTAINING HUMAN HEPATOCYTE CULTURES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE (FR) | 1992-05-12 | — | — | US | claimed |
| WO-1992005810-A1 | HYDROPHILIC PRESSURE SENSITIVE ADHESIVE FOR TOPICAL ADMINISTRATION OF HYDROPHOBIC DRUGS | MEDTRONIC, INC. (US) | 1992-04-16 | — | — | WO | claimed |
| EP-0143809-B1 | METHOD FOR OBTAINING HUMAN HEPATOCYTES CULTURES, CULTURES OBTAINED THEREBY AND BIOLOGICAL AND BIOCHEMICAL APPLICATIONS THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-01-18 | — | — | EP | claimed |
| US-4735895-A | INCUBATING HUMAN SKIN FIBROBLAST CULTURE; INFECTING WITH KIRSTEN MURINE SARCOMA VIRUS; EXPOSURE TO GLUCOCORTICOSTEROID; MONITORING LIPOGENIC ENZYME | ONCOTECH, INC. (US) | 1988-04-05 | — | — | US | claimed |